https://www.idival.org/wp-content/uploads/2022/05/cab-presentacion.jpg

CIBER incorporates IDIVALs group of infection and immunity of the digestive system

5 de March de 2017

Group of Infection and Immunity of the Digestive System of IDIVAL led by from Marqués de Valdecilla University Hospital and the University of Cantabria has just joined as a Group linked to CIBER. This Group focuses on the study of viral hepatitis where it has already become a national reference, and in liver fat deposition diseases, the great epidemic of the 21st century.


The objective of the Center for Biomedical Research in Network, CIBER, a public research consortium created by initiative of the Institute of Health Carlos III (ISCIII) is to further excellence research in Biomedicine and Health Sciences done in the National Health System and in the Science and Technology System. To this end efforts and interdisciplinary and multi-institutional research are combined with a preferential dedication of financial resources around knowledge networks formed by centres and research groups reporting to different administrations and public and private institutions.

The CIBER’s thematic area of Liver and Digestive Diseases (CIBEREHD) has the purpose of promoting and protecting health by furthering research. This work, whose scope includes both basic research and clinical and translational aspects, is based on the field of Liver and Digestive Diseases with the aim of innovating in the prevention of these diseases and promoting scientific and healthcare progress.

Currently CIBEREHD belongs to 50 groups of 30 centers distributed in 9 Autonomous Communities that work together in 4 corporate programs. In CIBEREHD are represented the best researchers of our country in the field of liver diseases.

The entry of this group of IDIVAL is a clear recognition of the level achieved with a evident growth in recent years due to the high quality scientific production and fundraising research.